ArticleThe Journal of infection2023
Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation.
Registry-linked trialAbstract readLetter
In one paragraph
Article in The Journal of infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05216588 (Pre-exposure Prophylaxis of SARS-CoV-2 Infection), which is not on this map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort.
Who cites it
4 citing papers in PubMed.
- Dose-dependent impact of tixagevimab-cilgavimab as primary prevention against SARS-CoV-2 in immunocompromised individuals.Scientific reports · 2025Article
- Article
- Living During COVID-19 While Immunocompromised: A Patient and Physician Perspective from France.Infectious diseases and therapy · 2024Article
- Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies.Blood advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Xavier de LamballerieUnité des Virus Émergents, INSERM-120, IRD-190, Aix-Marseille University, France.
Guillaume Martin-BlondelService des Maladies Infectieuses et Tropicales, CHU de Toulouse & Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Université Toulouse III.
Axelle DupontUniversité Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, Centre d'Investigation clinique-Epidémiologie Clinique 1425. Inserm, Department of Epidemiology Biostatistics and Clinical Research, AP-HP, Hôpital Bichat, F-75018 Paris, Paris, France.
Jacques IzopetCHU Toulouse, Hôpital Purpan, Laboratoire de Virologie, National Reference Center for Hepatitis E, Inserm UMR 1291, CNRS UMR5051, Université Toulouse III, 31000, Toulouse, France.
France MentréUniversité Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, Centre d'Investigation clinique-Epidémiologie Clinique 1425. Inserm, Department of Epidemiology Biostatistics and Clinical Research, AP-HP, Hôpital Bichat, F-75018 Paris, Paris, France.
Nassim KamarDépartement de Néphrologie et Transplantation d'Organes, CHU Rangueil 31059 Toulouse, France.
Brigitte AutranSorbonne-Université, Cimi-Paris, Inserm U1135. CNRS ERL8255, UPMC CR7, Team « NK and T cell immunity, infections and cancer», Paris, France.
Gilles PaintaudUniversité de Tours, EA4245 Transplantation, Immunology and Inflammation, Tours, France.
Sophie CaillardDepartment of Nephrology and Transplantation, Strasbourg University Hospital, Inserm UMR S1109 Labex Transplantex. Fédération de Médecine Translationnelle, 67000, Strasbourg, France.
Amandine le Bourgeoisservice d'hématologie clinique, CHU Nantes, 1 place Alexis Ricordeau 44000 Nantes, France.
Christophe RichezHôpital Pellegrin. CHU de Bordeaux. Service de Rhumatologie. Centre de référence des maladies autoimmunes systémiques rares (RESO). UMR-CNRS 5164, Université de Bordeaux, Bordeaux, France.
Lionel CouziNephrologie-Transplantation-Dialyse. CHU Bordeaux. Bordeaux. France CNRS-UMR 5164 Immuno ConcEpT. Université de Bordeaux, Bordeaux, France.
Aliénor XhaardService d'hématologie greffe Hôpital Saint-Louis, APHP, Université de Paris Cité, Paris, France.
Zora MarjanovicSorbonne University, Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, INSERM, UMRs 938, Paris, France.
Jerome AvouacUniversité de Paris Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP 27 rue du Faubourg Saint-Jacques 75014 Paris, France.
Caroline JacquetService Hématologie et Thérapies Cellulaires, CHRU Bretonneau, Tours, France.
Denis AnglicheauDepartment of Nephrology and kidney transplantation, Necker Hospital. APHP and Université de Paris Cité, Paris, France.
Morgane CheminantClinical Hematology, Necker-Enfants Malades University Hospital, AP-HP. F-75015, Université de Paris Cité, Paris, France.
Yazdan YazdanpanahUniversité Paris Cité, INSERM UMRS 1137 IAME, Paris. France.
Stéphanie N GuyenSorbonne université, Groupe Hospitalier Pitié-Salpêtrière APHP, service d'Hématologie clinique, Pavillon Georges Heuyer, 47-83 boulevard de l'Hôpital, 75651 Paris cedex 13. Sorbonne Université. Inserm CNRS 1135 « NK and T cell immunity. Virus and Cancer ». Centre d'Immunologie et des Pathologies Infectieuses (CIMI), UPMC UMRS CR7-Inserm U1135-CNRS ERL 8255, faculté de Médecine Sorbonne Université, Site Pitié-Salpêtrière, 91 boulevard de l'Hôpital, 75013 Paris, France.
Benjamin TerrierAssistance Publique-Hôpitaux de Paris, Département de Médecine Interne, Centre de Référence National pour les maladies auto-immunes systémiques rares. Hôpital Cochin Paris., Université Paris. France.
Jacques Eric GottenbergService de Rhumatologie, Hôpitaux Universitaires de Strasbourg, CNR RESO, Hôpitaux Universitaires de Strasbourg, Laboratoire d'Immunopathologie et de Chimie Thérapeutique. Institut de Biologie Moléculaire et Cellulaire (IBMC). CNRS UPR3572, 67000, Strasbourg, France.
Caroline BessonUniversité Paris-Saclay, UVSQ, CESP-INSERM1018, CH de Versailles. 78150, Le Chesnay, France.
Sophie LetrouDépartement d'Épidémiologie, Biostatistique et Recherche Clinique Unité de Recherche Clinique Paris Nord APHP.Nord - Université Paris Cité Hôpital Bichat - Claude-Bernard 46 rue Henri Huchard, 75877 Cedex 18, PARIS.
Sabrina KaliClinical Research Department, ANRS | Emerging infectious disease, PariSanté Campus | 2 rue d'Oradour-sur-Glane, 75015 Paris.
Denis AngoulvantService de Cardiologie, CHRU de Tours & EA4245 Transplantation Immunologie et Inflammation, Université de Tours. F37000 Tours, France.
Ventzislava Petrov SanchezANRS|Emerging Infectious Diseases, Department of Clinical Research, Paris, France.
Coralie TardivonDepartement of Epidemiology Biostatistics and Clinical Research. AP-HP. Hôpital Bichat, Paris, France.
Gilles BlanchoInstitut de Transplantation- Urologie - Néphrologie (ITUN) Hôtel Dieu - CHU de Nantes 30 bd Jean-Monnet, 44093, Nantes, France.
Vincent LévyDépartement de Recherche Clinique, Hôpital Avicenne. APHP, Université Sorbonne Paris Nord and CRESS INSERM U1153. ECSTRRA team. Electronic address: vincent.levy@aphp.fr.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, NeutralizingAntibodies, ViralAntibodies, MonoclonalDrug CombinationsHumansAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, Viralcilgavimab and tixagevimab drug combinationDrug Combinations
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT05216588ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.